Hyperliquid Strategies Inc Common Stock Q4 FY2026 earnings call

• Strategic Pivot: Hyperliquid Strategies has transitioned from holding a biotech business to becoming the largest publicly traded digital asset treasury company for the HYPE token, listing on NASDAQ with no debt.
• Treasury Management: The balance sheet holds 29.4 million HYPE tokens (valued at ~$1.9 billion as of June 30) and ~$150 million in cash/cash equivalents. The company maintains a disciplined approach, keeping cash reserves to buy tokens during dips or repurchase stock when trading below NAV multiples.
• Hyperliquid Ecosystem Growth: The underlying Hyperliquid blockchain is positioned strongly across four key areas: Perpetual Futures (dominant market position), Stablecoins (new revenue share agreements favoring the ecosystem), Real-World Assets (RWA) (significant volume growth since last November), and Prediction Markets (outcome markets going permissionless).
• Revenue Mechanism: 99% of Hyperliquid’s on-chain revenue is used programmatically to repurchase the HYPE token daily. On-chain revenue grew from $14 million in Q4 2024 to $324 million in Q3 2025.
• Valuation Metrics: The company monitors both Net Asset Value (NAV) including and excluding Deferred Tax Liability (DTL). The DTL (~$184 million) is a non-current GAAP requirement that only becomes payable if tokens are sold, which management currently has no intention of doing.

The company operates as a single-segment digital asset treasury company focused on the HYPE token. For the fiscal year ending June 30, 2026, the firm generated approximately $553 million in income related to its treasury assets. This income was primarily driven by unrealized gains on HYPE tokens, including appreciation from initial acquisition and strategic purchases of ~16.5 million tokens at an average price of ~$46.77. Additionally, the company recognized $9.5 million in staking and validator revenues. Operating costs were approximately $14 million for the year, with a significant decrease in Q4 following the divestiture of the legacy biotech business.

• Operating Expenses: CFO Brett Beldner indicated that operating expenses have reached a new steady state, with Q4 being representative of future quarters. He estimated a quarterly OPEX run rate of approximately $4 million, subject to change if new ecosystem investments arise.
• Token Acquisition Strategy: Management expressed confidence in continuing to deploy capital into HYPE tokens opportunistically. They noted that their average acquisition cost ($46.77) may tick upward as they continue buying in a rising market, but they remain open to using cash reserves to repurchase stock if it trades at a discount to NAV.

• Deferred Tax Liability: A significant deferred tax liability of ~$184 million exists due to embedded unrealized taxable gains on HYPE tokens under GAAP. While not a current cash obligation, it represents a real future liability if the company decides to liquidate its token holdings.
• Market Volatility: The company acknowledges high volatility in both the HYPE token and its own stock price, noting that external factors like crypto market cycles can significantly impact treasury values.
• Execution Risk in New Ventures: Management emphasized a highly selective approach to new ecosystem investments, rejecting over 95% of opportunities to avoid value destruction, implying risks associated with potential missed opportunities or misallocation if criteria are not strictly met.

Q: Analyst asked about the partnership with the Hyperliquid Policy Center for U.S. market entry, specifically regarding front-end/back-end structures and global KYC requirements.

A: CEO David Schamis confirmed that Hyperliquid is actively working to enter the U.S. market and is willing to assist regulators. However, he declined to provide specific details on the technical structure (e.g., global vs. regional KYC) to avoid preempting negotiations, stating only that the initiative is underway and supported by recent political signals.

Q: Analyst asked if HIP3/HIP4 markets requiring USDC backing would constrain stablecoin supply growth, and whether these catalysts are priced in.

A: CFO Brett Beldner explained that while cross-margining allows positions to offset, the requirement for USDC backing should still drive overall stablecoin supply growth. Schamis added that while the token price reacted to recent news, he believes the long-term upside remains significant given the conglomeration of positive developments.

Q: Analyst asked about the timing of ecosystem investments and the trajectory of operating expenses post-biotech divestiture.

A: Schamis stated they seek asymmetric upside opportunities rather than low-return projects, maintaining a strict 'no' ratio for most proposals. Beldner confirmed OPEX has stabilized at a ~$4 million quarterly run rate, though this could fluctuate if new high-potential investments are pursued.

Q: Analyst asked about the adoption impact of the single margin account concept and how the company views NAV calculations involving Deferred Tax Liability (DTL).

A: Schamis highlighted that the single margin account significantly improves liquidity and reduces bid-ask spreads by making it easier for market makers to operate across asset classes, giving Hyperliquid a competitive edge over incumbents. Regarding NAV, management uses both metrics (with and without DTL) for decision-making, particularly for equity issuances, aiming for proceeds above 1.1x MNAV.